Hippocratic AI builds clinically validated conversational AI agents that assist healthcare teams and patients across the care continuum. Our agents prioritize safety and clinical correctness — they do not diagnose or prescribe — and are trained on and tested with hundreds of thousands of clinician-reviewed interactions and over 150 million clinical interactions to improve patient outcomes and operational efficiency.

We offer 1,000+ specialty AI agents for use cases such as readmission prevention, chronic care management, vaccination and screening outreach, medication reconciliation, adverse event detection, and study follow-up. Customers have reported measurable results (for example, 30% reduction in readmissions and 12x average ROI). Hippocratic AI is backed by $404M in funding from investors including General Catalyst, a16z BioHealth, CapitalG, and others, and focuses on research, safety-first architectures, and compliance.